Fibromyalgia Trial Endpoints Should Be Validated In Real Time – FDA Cmte.
Executive Summary
Endpoints of fibromyalgia efficacy trials should be validated in "real time" with pain as one of the primary outcome measures, FDA's Arthritis Advisory Committee recommended June 23
You may also be interested in...
Statistics Bedeviled Cymbalta Fibromyalgia NDA, Derail Chronic Pain Claim
The statistical dispute behind Lilly's withdrawal of its chronic pain sNDA for Cymbalta should come as no surprise to the sponsor - the issue was previewed during FDA's review of an earlier duloxetine indication, fibromyalgia
Statistics Bedeviled Cymbalta Fibromyalgia NDA, Derail Chronic Pain Claim
The statistical dispute behind Lilly's withdrawal of its chronic pain sNDA for Cymbalta should come as no surprise to the sponsor - the issue was previewed during FDA's review of an earlier duloxetine indication, fibromyalgia
Cymbalta Finds Divergent FDA, European Standards For Fibromyalgia Approval
The stance of U.S and European regulators on fibromyalgia drug development is diverging, as Lilly has discovered in pursuing a fibromyalgia claim for Cymbalta (duloxetine).
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: